Tel: 01789 267520

Latest News: Treatments & Research

Latest NICE Community Update re Nusinersen

12 November 2018 / Posted in: Treatments & Research

This latest SMA Community update from NICE doesn't give a decision yet but states that talks are still progressing.

Read full story

Biogen Statement to SMA Community re: EAP for SMA Type 1 in England, Wales and Northern Ireland

01 November 2018 / Posted in: Treatments & Research

Despite our urgent request, Biogen has not extended the cut off for this programme to 1st December. It ends now for any newly diagnosed infants. Read their community statement here.

Read full story

Update on Access to Nusinersen

26 October 2018 / Posted in: Treatments & Research

Thank you to the patient and clinical experts who strongly advocated for access to nusinersen at NICE’s committee meeting this week; to clinicians, families and adults who: expressed their views in their submissions to NICE; wrote letters to MPs, NICE, NHS England and Biogen; were there on the day.

Read full story

AveXis Community Update on Submitting their Application for AVXS-101

19 October 2018 / Posted in: Treatments & Research

AveXis yesterday submitted their regulatory applications for AVXS-101 in the U.S., Europe and Japan for use in infants with SMA Type 1. This is an important initial step toward the potential approval of AVXS-101, a gene replacement therapy candidate for the treatment of the underlying root cause of SMA.

Read full story

$3 million 'Breakthrough' prize for Developers Behind Spinraza

18 October 2018 / Posted in: Treatments & Research

An article in The Guardian, published yesterday, describes how C Frank Bennett, senior vice president of research at Ionis Pharmaceuticals, and Adrian Krainer of Cold Spring Harbor Laboratory, have won the prize for developing Spinraza.

Read full story

SMA UK’s submission to NICE’s scoping consultation on AVXS-101 treatment for infants with SMA Type 1

17 October 2018 / Posted in: Treatments & Research

England’s regulatory body, NICE, has invited a wide range of clinical and patient groups to comment on this treatment. You can read what we have said to NICE here.

Read full story

Biogen Response to the Charities' August 28th Joint Letter

09 October 2018 / Posted in: Treatments & Research

In our letter, we urged both Biogen and NHS England to be as flexible as possible in their discussion on the price of nusinersen. Read their reply here.

Read full story

Consultation About Spinal Muscular Atrophy UK's Priorities

09 October 2018 / Posted in: Information, Treatments & Research, Support

We are now starting to work out priorities for the new organisation, including how and when the funds we hope to raise should be spent. We are very keen to hear the views of as many people in the SMA Community as possible. The survey closes on 11th November.

Read full story

Biogen’s ‘Biomarkers’ Research to Find Ways to Tell Whether a Medication Has Been Successful

09 October 2018 / Posted in: Treatments & Research

At the 23rd International Annual Congress of the World Muscle Society, pharmaceutical company Biogen presented the findings of blood tests done on over 300 participants receiving nusinersen in their clinical trials.

Read full story

New Results from Biogen’s NURTURE Study of Pre-Symptomatic Infants with SMA

09 October 2018 / Posted in: Treatments & Research

At the 23rd International Annual Congress of the World Muscle Society, pharmaceutical company Biogen announced its latest findings.

Read full story